Abstract Objective To study the role of miR-431 in lung development and morphology. Methods According to the stage of lung development in rats, Sprague-Dawley rats at embryonic day 16 (E16), embryonic day (E19), embryonic day (E21), postnatal day 1 (P1), postnatal day 3 (P3), postnatal day 7 (P7), postnatal day 14 (P14) and 10 weeks after birth (P10 weeks) were selected, and lung tissue samples were collected for observation. Hematoxylin-eosin staining and transmission electron microscopy were performed to observe the morphology of lung tissue. Fluorescence in situ hybridization and real-time PCR were used to measure the expression of miR-431 during the critical stages of lung development (E19, E21 and P3). Results The E19 group had the formation of the lamellar body and type Ⅱ alveolar epithelial cells in the fetal lung tissue. The number of lamellar bodies increased with the increasing gestational age, with aggregation and excretion. Pulmonary alveoli formed rapidly, the lung interstitium became thinner, and the microvascular system became mature after birth. Fluorescence in situ hybridization and real-time PCR showed that the expression of miR-431 gradually decreased with the increasing gestational age (P < 0.05). Conclusions The systematic and continuous morphological data of lung development is obtained in this experiment. In addition, miR-431 may play an important role in the negative regulation of lung development, which provides basis and direction for further research on the mechanism of lung development and related diseases.
SHEN Yan-Qing,YANG Yang,SUN Zhong-Yi et al. Continuous expression of miR-431 during lung development in Sprague-Dawley rats[J]. CJCP, 2019, 21(3): 287-293.
SHEN Yan-Qing,YANG Yang,SUN Zhong-Yi et al. Continuous expression of miR-431 during lung development in Sprague-Dawley rats[J]. CJCP, 2019, 21(3): 287-293.
de Mello RR, Rodrigues Reis AB, da Silva KS. Cognitive performance of premature infants:association between bronchopulmonary dysplasia and cognitive skills. Crosssectional study[J]. Sao Paulo Med J, 2017, 135(4):383-390.
[2]
Schmalisch G, Wilitzki S, Roehr CC, et al. Development of lung function in very low birth weight infants with or without bronchopulmonary dysplasia:longitudinal assessment during the frst 15 months of corrected age[J]. BMC Pediatr, 2012, 12:37.
[3]
Stocks J, Hislop A, Sonnappa S. Early lung development:lifelong effect on respiratory health and disease[J]. Lancet Respir Med, 2013, 1(9):728-742.
[4]
Ortiz LE, McGrath-Morrow SA, Sterni LM, et al. Sleep disordered breathing in bronchopulmonary dysplasia[J]. Pediatr Pulmonol, 2017, 52(12):1583-1591.
[5]
Bhaskaran M, Wang Y, Zhang H, et al. MicroRNA-127 modulates fetal lung development[J]. Physiological genomics, 2009, 37(3):268-278.
[6]
Lu Y, Thomson JM, Wong HY, et al. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells[J]. Dev Biol, 2007, 310(2):442-453.
[7]
Yang Y, Kai G, Pu XD, et al. Expression profle of microRNAs in fetal lung development of Sprague-Dawley rats[J]. Int J Mol Med, 2012, 29(3):393-402.
[8]
Kan Q, Ding S, Yang Y, et al. Expression profile of plasma microRNAs in premature infants with respiratory distress syndrome[J]. Mol Med Rep, 2015, 12(2):2858-2864.
[9]
Hussain M, Xu C, Lu M, et al. Wnt/beta-catenin signaling links embryonic lung development and asthmatic airway remodeling[J]. Biochim Biophys Acta, 2017, 1863(12):3226-3242.
El-Gendy N, Kaviratna A, Berkland C, et al. Delivery and performance of surfactant replacement therapies to treat pulmonary disorders[J]. Ther Deliv, 2013, 4(8):951-980.
[12]
Wang H, Gao X, Liu C, et al. Morbidity and mortality of neonatal respiratory failure in China:surfactant treatment in very immature infants[J]. Pediatrics, 2012, 129(3):e731-e740.
[13]
Strueby L, Thebaud B. Advances in bronchopulmonary dysplasia[J]. Expert Rev Respir Med, 2014, 8(3):327-338.
[14]
Ali Z, Schmidt P, Dodd J, et al. Bronchopulmonary dysplasia:a review[J]. Arch Gynecol Obstet, 2013, 288(2):325-333.
[15]
Jensen EA, Foglia EE, Schmidt B. Evidence-based pharmacologic therapies for prevention of bronchopulmonary dysplasia:application of the grading of recommendations assessment, development, and evaluation methodology[J]. Clin Perinatol, 2015, 42(4):755-779.
Condo V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome:are risk factors the same in preterm and term infants?[J]. J Matern Fetal Neonatal Med, 2017, 30(11):1267-1272.
[20]
Pan L, Ren F, Rong M, et al. Correlation between downexpression of miR-431 and clinicopathological signifcance in HCC tissues[J]. Clin Transl Oncol, 2015, 17(7):557-563.
[21]
Liu Y, Li L, Liu Z, et al. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma[J]. Cancer Biomark, 2018, 22(4):727-732.
[22]
Yang J, Zhu H, Jin Y, et al. MiR-431 inhibits cell proliferation and induces cell apoptosis by targeting CDK14 in pancreatic cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(14):4493-4499.
[23]
Su WB, Liu ZY. MiR-431 inhibits colorectal cancer cell invasion via repressing CUL4B[J]. Eur Review Med Pharmacol Sci, 2018, 22(10):3047-3052.
[24]
Wertz MH, Winden K, Neveu P, et al. Cell-type-specifc miR-431 dysregulation in a motor neuron model of spinal muscular atrophy[J]. Hum Mol Genet, 2016, 25(11):2168-2181.
[25]
Lee KP, Shin YJ, Panda AC, et al. miR-431 promotes differentiation and regeneration of old skeletal muscle by targeting Smad4[J]. Genes Dev, 2015, 29(15):1605-1617.
[26]
Wu R, Li H, Li T, et al. Myostatin regulates miR-431 expression via the Ras-Mek-Erk signaling pathway[J]. Biochem Biophys Res Commun, 2015, 461(2):224-229.
